financetom
Business
financetom
/
Business
/
Appfolio Insider Bought Shares Worth $4,778,054, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Appfolio Insider Bought Shares Worth $4,778,054, According to a Recent SEC Filing
Jun 10, 2025 12:29 AM

03:14 AM EDT, 06/10/2025 (MT Newswires) -- Timothy K Bliss, Director, on June 05, 2025, executed a purchase for 22,000 shares in Appfolio ( APPF ) for $4,778,054. Following the Form 4 filing with the SEC, Bliss has control over a total of 22,000 Class A common shares of the company, with 22,000 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1433195/000095017025084057/xslF345X05/ownership.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cerrado Gold Cuts 2025 Production Guidance as Details Q3 Production and 2026 Plan For Minera Don Nicolas Mine in Argentina
Cerrado Gold Cuts 2025 Production Guidance as Details Q3 Production and 2026 Plan For Minera Don Nicolas Mine in Argentina
Oct 20, 2025
09:22 AM EDT, 10/20/2025 (MT Newswires) -- Cerrado Gold ( CRDOF ) on Monday reduced its 2025 gold equivalent production guidance at the Minera Don Nicolas mine in Argentina, while its output dropped year over year in the third quarter. The company cut its guidance to a range of 50,000-55,000 ounces from the previous target of 55,000-60,000 ounces, citing a...
Immutep Says its Mid-Stage Trial of Eftilagimod Alfa Meets Primary Endpoint of Tumor Hyalinization/Fibrosis
Immutep Says its Mid-Stage Trial of Eftilagimod Alfa Meets Primary Endpoint of Tumor Hyalinization/Fibrosis
Oct 20, 2025
09:20 AM EDT, 10/20/2025 (MT Newswires) -- Immutep ( IMMP ) said Monday that its Eftisarc-neo mid-stage study of eftilagimod alfa with radiotherapy plus Keytruda has met its primary endpoint and significantly exceeded the trial's prespecified 35% tumor hyalinization/fibrosis. The company said the trial enrolled 38 participants and found that the novel combination with eftilagimod alfa resulted in a median...
Radiopharm Theranostics Says Data From Clinical Programs Expected in Near Term
Radiopharm Theranostics Says Data From Clinical Programs Expected in Near Term
Oct 20, 2025
09:20 AM EDT, 10/20/2025 (MT Newswires) -- Radiopharm Theranostics ( RADX ) said Monday it expects to provide topline data readouts from its four lead clinical programs in the near term. The company also said it plans to begin phase 1 trials for RV01 and RAD402 antibody assets by year-end. Radiopharm said data from the first two cohorts in its...
BRIEF-NxGen Brands, Inc. Announces the Official Acquisition of Top Handmade Fudge and Candy Company, Genesee Candy Land and Genesee Fudge Factory
BRIEF-NxGen Brands, Inc. Announces the Official Acquisition of Top Handmade Fudge and Candy Company, Genesee Candy Land and Genesee Fudge Factory
Oct 20, 2025
Oct 20 (Reuters) - Nxgen Brands Inc ( NXGB ): * NXGEN BRANDS, INC. ( NXGB ) ANNOUNCES THE OFFICIAL ACQUISITION OF TOP HANDMADE FUDGE AND CANDY COMPANY, GENESEE CANDY LAND AND GENESEE FUDGE FACTORY Source text: Further company coverage: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved